医学
艾瑞布林
紫杉烷
转移性乳腺癌
帕妥珠单抗
危险系数
内科学
曲妥珠单抗
多西紫杉醇
肿瘤科
临床终点
人口
乳腺癌
癌症
随机对照试验
置信区间
环境卫生
作者
Toshinari Yamashita,Shigehira Saji,Toshimi Takano,Yoichi Naito,Michiko Tsuneizumi,Akiyo Yoshimura,Masato Takahashi,Junji Tsurutani,Tsuguo Iwatani,Masahiro Kitada,Hiroshi Tada,Natsuko Mori,Toru Higuchi,Tsutomu Iwasa,Kazuhiro Araki,Kei Koizumi,Hiroki Hasegawa,Yohei Uchida,Satoshi Morita,Norikazu Masuda
摘要
The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.
科研通智能强力驱动
Strongly Powered by AbleSci AI